Janney Montgomery Scott LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,715 shares of the biopharmaceutical company’s stock after selling 1,562 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Regeneron Pharmaceuticals were worth $2,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $130,000. Sterling Investment Advisors Ltd. boosted its position in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares in the last quarter. FNY Partners Fund LP boosted its position in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares in the last quarter. IFP Advisors Inc boosted its position in Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $206,000. 66.67% of the stock is currently owned by institutional investors.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $388.95 on Monday. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a market capitalization of $41,788.40, a PE ratio of 33.68, a P/E/G ratio of 1.53 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the previous year, the company posted $3.13 earnings per share. The company’s revenue was up 23.0% compared to the same quarter last year. analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Morgan Stanley reaffirmed an “equal weight” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Barclays downgraded Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Oppenheimer reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 27th. Finally, J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th. Two research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average price target of $465.40.

In related news, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Janney Montgomery Scott LLC Sells 1,562 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/18/janney-montgomery-scott-llc-sells-1562-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related stocks with our FREE daily email newsletter.